Form 4: Anixa Biosciences Director Increases Stake in Company
SEC Form 4
Director Lewis H. Titterton Jr. reports purchasing additional shares of Anixa Biosciences, Inc. on July 30 and 31, 2024.
Summary
- On July 30, 2024, Lewis H. Titterton Jr., a director of Anixa Biosciences, Inc., purchased 21,646 shares of common stock at a price of $3.06 per share.
- Following this transaction, Titterton directly owned 890,754 shares.
- On July 31, 2024, Titterton purchased an additional 5,580 shares at $3.23 per share, increasing his direct ownership to 896,334 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the impact is limited as it's a single director's activity.
Positives
- A director increasing their stake in the company can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, but should be considered alongside other factors.
Stakeholder Impact
- Shareholders may view the director's purchase as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 07/30/2024 | Director purchased 21,646 shares at $3.06 per share. |
| 07/31/2024 | Director purchased 5,580 shares at $3.23 per share. |
| 08/01/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.